Analysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kezar Life Sciences (KZR – Research Report), RVL Pharmaceuticals (RVLP – Research Report) and Finch Therapeutics Group (FNCH – Research Report) with bullish sentiments.

Kezar Life Sciences (KZR)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences, with a price target of $21.00. The company’s shares closed last Thursday at $7.23.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -30.5% and a 21.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Fresh Tracks Therapeutics, and Aquestive Therapeutics.

Currently, the analyst consensus on Kezar Life Sciences is a Moderate Buy with an average price target of $21.00.

See today’s best-performing stocks on TipRanks >>

RVL Pharmaceuticals (RVLP)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on RVL Pharmaceuticals today and set a price target of $5.00. The company’s shares closed last Thursday at $1.44.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 1.4% and a 38.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Crinetics Pharmaceuticals.

Currently, the analyst consensus on RVL Pharmaceuticals is a Moderate Buy with an average price target of $3.50.

Finch Therapeutics Group (FNCH)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Finch Therapeutics Group, with a price target of $17.00. The company’s shares closed last Thursday at $1.05, close to its 52-week low of $1.01.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 19.4% and a 32.5% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Aridis Pharmaceuticals, and Achieve Life Sciences.

Finch Therapeutics Group has an analyst consensus of Moderate Buy, with a price target consensus of $17.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on KZR:

• H.C. Wainwright Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
• Vigil Neuroscience Inc (VIGL) Receives a Buy from H.C. Wainwright
• Catalyst Pharma (CPRX) Receives a Buy from H.C. Wainwright
• H.C. Wainwright Remains a Buy on Werewolf Therapeutics (HOWL)
• H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)